MLICM
LGND icon

Metropolitan Life Insurance Company (MetLife)’s Ligand Pharmaceuticals LGND Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-897
Closed -$65.6K – 1170
2024
Q1 		$65.6K Sell
897
-120
-12% -$8.85K ﹤0.01% 1271
2023
Q4 		$72.6K Hold
1,017
– – ﹤0.01% 1251
2023
Q3 		$60.9K Buy
1,017
+105
+12% +$6.91K ﹤0.01% 1292
2023
Q2 		$65.8K Buy
912
+73
+9% +$5.48K ﹤0.01% 1267
2023
Q1 		$61.7K Sell
839
-97
-10% -$6.89K ﹤0.01% 1275
2022
Q4 		$62.5K Sell
936
-455
-33% -$29.6K ﹤0.01% 1338
2022
Q3 		$74.7K Sell
1,391
-206
-13% -$12.1K ﹤0.01% 1194
2022
Q2 		$88.9K Hold
1,597
– – ﹤0.01% 1120
2022
Q1 		$112K Sell
1,597
-4,894
-75% -$355K ﹤0.01% 1122
2021
Q4 		$625K Hold
6,491
– – 0.01% 1276
2021
Q3 		$564K Sell
6,491
-4,491
-41% -$347K 0.01% 1376
2021
Q2 		$899K Buy
10,982
+441
+4% +$36.7K 0.01% 1096
2021
Q1 		$1M Sell
10,541
-717
-6% -$67.8K 0.02% 929
2020
Q4 		$698K Sell
11,258
-106
-0.9% -$6.04K 0.01% 1138
2020
Q3 		$676K Sell
11,364
-237
-2% -$16.2K 0.01% 996
2020
Q2 		$809K Sell
11,601
-3,169
-21% -$201K 0.01% 867
2020
Q1 		$670K Sell
14,770
-794
-5% -$45K 0.01% 895
2019
Q4 		$1.01M Sell
15,564
-1,864
-11% -$125K 0.02% 895
2019
Q3 		$1.08M Sell
17,428
-1,495
-8% -$93.9K 0.02% 816
2019
Q2 		$1.35M Sell
18,923
-355
-2% -$26.1K 0.02% 726
2019
Q1 		$1.51M Sell
19,278
-548
-3% -$41.5K 0.03% 633
2018
Q4 		$1.68M Buy
19,826
+9,003
+83% +$960K 0.03% 526
2018
Q3 		$1.85M Hold
10,823
– – 0.03% 572
2018
Q2 		$1.4M Buy
10,823
+641
+6% +$71.5K 0.02% 749
2018
Q1 		$1.05M Sell
10,182
-383
-4% -$37.9K 0.01% 883
2017
Q4 		$903K Sell
10,565
-11,152
-51% -$967K 0.01% 948
2017
Q3 		$1.84M Hold
21,717
– – 0.01% 963
2017
Q2 		$1.65M Hold
21,717
– – 0.01% 1014
2017
Q1 		$1.43M Hold
21,717
– – 0.01% 1072
2016
Q4 		$1.38M Hold
21,717
– – 0.01% 1129
2016
Q3 		$1.38M Sell
21,717
-433
-2% -$31.8K 0.01% 1109
2016
Q2 		$1.65M Buy
22,150
+968
+5% +$71.8K 0.01% 1010
2016
Q1 		$1.42M Buy
21,182
+1,496
+8% +$90.9K 0.01% 1018
2015
Q4 		$1.33M Hold
19,686
– – 0.01% 1038
2015
Q3 		$1.05M Hold
19,686
– – 0.01% 1165
2015
Q2 		$1.24M Sell
19,686
-5,571
-22% -$304K 0.01% 1159
2015
Q1 		$1.22M Hold
25,257
– – 0.01% 1104
2014
Q4 		$838K Hold
25,257
– – 0.01% 1447
2014
Q3 		$740K Hold
25,257
– – 0.01% 1465
2014
Q2 		$981K Buy
25,257
+1,812
+8% +$73.5K 0.01% 1362
2014
Q1 		$984K Sell
23,445
-252
-1% -$10.5K 0.01% 1360
2013
Q4 		$778K Buy
23,697
+314
+1% +$10.2K 0.01% 1507
2013
Q3 		$631K Buy
23,383
+1,464
+7% +$41.2K ﹤0.01% 1596
2013
Q2 		$512K Buy
+21,919
New +$394K ﹤0.01% 1678

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LGND Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 897 shares — an estimated $65.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LGND in Q2 2013 and held it in 44 quarters. The position peaked at $1.85M in Q3 2018. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 897 Ligand Pharmaceuticals shares in Q2 2024, an estimated $65.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 44 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Ligand Pharmaceuticals position peaked at $1.85M in Q3 2018.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.